Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib

Kenichiro Kudo; Keita Kawakado; Tomoka Kawajiri; Tatsuya Nishi; Go Makimoto; Tomoki Tamura; Shoichi Kuyama; Mitsune Tanimoto

doi:10.2169/internalmedicine.4449-20

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib

Intern Med. 2020 Jul 15;59(14):1739-1740. doi: 10.2169/internalmedicine.4449-20. Epub 2020 Apr 16.

Authors

Kenichiro Kudo¹, Keita Kawakado¹, Tomoka Kawajiri¹, Tatsuya Nishi¹, Go Makimoto¹, Tomoki Tamura¹, Shoichi Kuyama¹, Mitsune Tanimoto¹

Affiliation

¹ Department of Respiratory Medicine, Iwakuni Clinical Center, Japan.

Abstract

The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions from EGFR-mutation-positive NSCLC in an elderly patient. This case report demonstrates that dacomitinib can be an essential treatment option for patients with brain metastases.

Keywords: brain metastasis; dacomitinib; non-small cell lung cancer.

Publication types

Case Reports

MeSH terms

Aged
Brain Neoplasms / drug therapy*
Carcinoma, Non-Small-Cell Lung / drug therapy*
ErbB Receptors / genetics
Female
Humans
Lung Neoplasms / drug therapy*
Mutation
Neoplasm Metastasis / drug therapy*
Quinazolinones / adverse effects*
Quinazolinones / therapeutic use*

Substances

Quinazolinones
EGFR protein, human
ErbB Receptors